Physician profile
Jose Concepcion
NPI 1699183129
$13,955.80
in general payments reported to CMS, 2019-2025
53 companies · $1,570 in 2025
The $1,570 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $522 · 2021: $2,546 · 2022: $2,442 · 2023: $3,530 · 2024: $2,740 · 2025: $1,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,641 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,640.99 |
| Education | $198.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,942.68 | 2019-2025 | Blincyto, Kyprolis, Xgeva |
| E.R. Squibb & Sons, L.L.C. | $902.54 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Genzyme Corporation | $848.07 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $708.89 | 2019-2025 | Erleada, Darzalex, Rybrevant |
| Abbvie INC. | $588.46 | 2021-2025 | Venclexta, Epkinly |
| Eisai INC. | $578.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $574.06 | 2019-2025 | Enhertu, Calquence, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $486.16 | 2021-2023 | Iclusig, Vonvendi |
| Astellas Pharma US INC | $481.75 | 2022-2024 | Xospata, Padcev |
| Rigel Pharmaceuticals, INC. | $437.93 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Novartis Pharmaceuticals Corporation | $429.12 | 2021-2025 | |
| Incyte Corporation | $424.02 | 2022-2025 | Monjuvi, Monjuvi, Jakafi |
| Merck Sharp & Dohme LLC | $391.67 | 2020-2025 | Keytruda, Keytruda Qlex |
| Tempus Ai, INC | $360.17 | 2024-2025 | Xt Cdx |
| Pbg Puerto Rico LLC | $352.84 | 2019-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $352.69 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Lilly USA, LLC | $348.11 | 2021-2024 | Jaypirca |
| Sobi, INC | $331.51 | 2023-2024 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $307.33 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Adaptive Biotechnologies Corporation | $277.87 | 2024-2025 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $249.46 | 2023 | Ultomiris |
| Genmab U.S., INC. | $234.81 | 2023-2024 | Epkinly |
| Taiho Oncology, INC. | $233.02 | 2021-2025 | |
| Genentech USA, INC. | $190.73 | 2021-2025 | Polivy, Tecentriq, Lunsumio |
| Pfizer INC. | $187.04 | 2021-2025 | |
| Seagen INC. | $173.23 | 2022-2023 | Adcetris, Tukysa |
| Exelixis INC. | $155.00 | 2022-2025 | Cabometyx |
| Adc Therapeutics America, INC. | $136.75 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.34 | 2020-2022 | |
| Janssen Biotech, INC. | $99.95 | 2021 | |
| Cti Biopharma Corp. | $89.06 | 2022 | |
| Kite Pharma, INC. | $87.01 | 2019 | |
| Springworks Therapeutics, INC. | $83.77 | 2024-2025 | Ogsiveo |
| Celgene Corporation | $78.95 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $76.56 | 2019 | |
| Bayer Puerto Rico INC. | $67.46 | 2024-2025 | Stivarga, Nubeqa, Vitrakvi |
| Puma Biotechnology, INC. | $65.73 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $65.45 | 2023 | Xpovio |
| Sanofi-Aventis U.S. LLC | $64.29 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $46.45 | 2024-2025 | Libtayo |
| Beigene USA, INC. | $40.58 | 2021-2024 | Brukinsa |
| Verity Pharmaceuticals INC. | $38.00 | 2022-2025 | Trelstar |
| Caris Mpi, INC. | $37.61 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $28.30 | 2025 | Orserdu |
| Mirati Therapeutics, INC. | $24.53 | 2023 | Krazati |
| Global Blood Therapeutics, INC. | $24.00 | 2022 | |
| Aveo Pharmaceuticals, INC. | $23.70 | 2024 | |
| Pharmaand Gmbh | $23.50 | 2025 | Rubraca |
| Tolmar, INC. | $23.50 | 2025 | Eligard, Rubraca |
| Gilead Sciences, INC. | $23.06 | 2025 | Trodelvy |
| Morphosys, US INC. | $20.36 | 2022 | |
| Blueprint Medicines Corporation | $20.07 | 2024 | Ayvakit |
| Sun Pharmaceutical Industries INC. | $18.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Concepcion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.